- Home
- IGMS vs RGR Comparison
IGMS vs RGR Comparison
Compare IGMS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- RGR
- Stock Information
- Founded
- IGMS 1993
- RGR 1949
- Country
- IGMS United States
- RGR United States
- Employees
- IGMS N/A
- RGR N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- IGMS Health Care
- RGR Industrials
- Exchange
- IGMS Nasdaq
- RGR Nasdaq
- Market Cap
- IGMS 528.6M
- RGR 610.8M
- IPO Year
- IGMS 2019
- RGR N/A
- Fundamental
- Price
- IGMS $7.48
- RGR $36.21
- Analyst Decision
- IGMS Buy
- RGR
- Analyst Count
- IGMS 8
- RGR 0
- Target Price
- IGMS $16.25
- RGR N/A
- AVG Volume (30 Days)
- IGMS 213.0K
- RGR 157.2K
- Earning Date
- IGMS 11-08-2024
- RGR 10-30-2024
- Dividend Yield
- IGMS N/A
- RGR 1.90%
- EPS Growth
- IGMS N/A
- RGR N/A
- EPS
- IGMS N/A
- RGR 1.73
- Revenue
- IGMS $2,918,000.00
- RGR $520,485,000.00
- Revenue This Year
- IGMS $386.95
- RGR N/A
- Revenue Next Year
- IGMS N/A
- RGR $4.81
- P/E Ratio
- IGMS N/A
- RGR $21.01
- Revenue Growth
- IGMS 57.64
- RGR N/A
- 52 Week Low
- IGMS $6.17
- RGR $35.61
- 52 Week High
- IGMS $22.50
- RGR $48.20
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- RGR 36.09
- Support Level
- IGMS $7.00
- RGR $35.61
- Resistance Level
- IGMS $10.80
- RGR $37.17
- Average True Range (ATR)
- IGMS 1.02
- RGR 0.84
- MACD
- IGMS -0.10
- RGR -0.00
- Stochastic Oscillator
- IGMS 10.39
- RGR 19.29
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.